发明授权
- 专利标题: Treatment drug for autoimmune diseases and allergic diseases
- 专利标题(中): 自身免疫性疾病和过敏性疾病的治疗药物
-
申请号: US13701408申请日: 2011-06-02
-
公开(公告)号: US08858944B2公开(公告)日: 2014-10-14
- 发明人: Koichi Kino , Toshihiro Kai , Mitsuhiro Matsumoto , Masunori Kajikawa , Masahito Sugiura , Emi Shimizu
- 申请人: Koichi Kino , Toshihiro Kai , Mitsuhiro Matsumoto , Masunori Kajikawa , Masahito Sugiura , Emi Shimizu
- 申请人地址: JP Osaka
- 专利权人: Sumitomo Dainippon Pharma Co., Ltd.
- 当前专利权人: Sumitomo Dainippon Pharma Co., Ltd.
- 当前专利权人地址: JP Osaka
- 代理机构: Leydig, Voit & Mayer, Ltd.
- 优先权: JP2010-127316 20100602
- 国际申请: PCT/JP2011/062741 WO 20110602
- 国际公布: WO2011/152503 WO 20111208
- 主分类号: A61K39/395
- IPC分类号: A61K39/395 ; G01N33/68 ; G01N33/50 ; C12Q1/68 ; C07K16/28 ; A61K39/00
摘要:
The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.
公开/授权文献
信息查询